POXEL news, videos and press releases - Page 4
For more news please use our advanced search feature.
POXEL - More news...
POXEL - More news...
- Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020
- Poxel Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 2020
- Poxel Announces Participation at Several Upcoming Scientific and Investor Conferences
- Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020
- Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French Government
- Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator
- Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting
- Poxel Announces Participation at Upcoming Scientific and Investor Conferences
- Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update
- Poxel to Host Conference Call for First Half 2020 Financial Results on September 15, 2020
- Poxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Patients
- Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma
- Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2020
- Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting
- Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH
- Poxel Announces Participation in Upcoming Virtual Investor Conferences
- Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases
- Poxel Successfully Raises €17.7 Million in a Capital Increase
- Poxel Announces Notice of its Annual General Meeting to be Held on June 24, 2020
- Poxel Announces First Quarter 2020 Financial and Corporate Update
- Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics
- Poxel Announces Availability of 2019 Universal Registration Document and Provides Business Update
- Poxel Reports Financial Results for Full Year 2019 and Provides Corporate Update
- Poxel to Host Conference Call for Full Year 2019 Financial Results and Provide Corporate Update on March 26, 2020 at 2:30 pm EDT
- Poxel to Report Full Year 2019 Financial Results and Host Conference Call on March 26, 2020
- Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update
- Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress
- Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
- Poxel Announces its Financial Calendar for 2020
- Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program
